US2268915A - Method and material for detoxifying local anesthetics - Google Patents

Method and material for detoxifying local anesthetics Download PDF

Info

Publication number
US2268915A
US2268915A US276236A US27623639A US2268915A US 2268915 A US2268915 A US 2268915A US 276236 A US276236 A US 276236A US 27623639 A US27623639 A US 27623639A US 2268915 A US2268915 A US 2268915A
Authority
US
United States
Prior art keywords
procaine
salts
local anesthetics
butyn
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US276236A
Inventor
Wastl Helene
Beutner Reinhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAHNEMANN RES FOUNDATION
HAHNEMANN RESEARCH FOUNDATION
Original Assignee
HAHNEMANN RES FOUNDATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAHNEMANN RES FOUNDATION filed Critical HAHNEMANN RES FOUNDATION
Priority to US276236A priority Critical patent/US2268915A/en
Application granted granted Critical
Publication of US2268915A publication Critical patent/US2268915A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Definitions

  • Our invention refers generally to the detoxifia point of viewof holding the anesthetic 10- cally at the place of injectionhas a definitely practical significance; and for that reason adrenaline is usually added routinely to local anesthetics.
  • adrenaline is a highlytoxic substance even in conjunction with a local anesthetic. Since it is diflicult to determine in advance the undue sensitivity of such individuals, it becomes eminently desirable to discover materials to be added to local anesthetics for the purpose of delaying their absorption, whether it be done by increasing the density of the membranes or by establishing local vasoconstruction. be harmless to the individual if they are to replace the adrenaline that accompanies the human use of local anesthetics.
  • Local anesthetics act on the central nervous system as a general poison when absorbed at a sufficiently rapid rate and with their elimination lagging behind at a certain rate. Convulsions and equilibrium disturbances are largely of a cortical origin. Therefore, one can determine, when studying the convulsions caused by toxic doses. of local anesthetics in animals, those substances, mostly Ca salts, which lead to a lesser incidence or to a complete disappearance of the aforesaid toxic effects. Although we have observed the effectiveness of our means for de- Such materials, obviously, must substances (dominant receptors) at the site of the action and also-with secondary receptors apart from the site of the action.
  • the site of the action may be more or less irritable and the dominant receptors may be more or less accessible to the drug.
  • the factors that influence the rate of the chemical destruction of the drug in the animal body those that change the action of the drug by influencing its milieu and those that modify the distribution of the drug between the dominant and the secondary receptors.
  • two drugs have the same dominant receptors, it is likely that one drug will be more easily absorbed than the other, i. e., the recognized phenomenon of replacement becomes evident. Accordingly, detoxification of local anesthetics by the addition to them of other substances cannot be attributed solely to a single mechanism,, as, for
  • the same agencies in smaller dosage are safely applicable, as attested, by clinical experience, to humans by replacing adrenaline with the Ca salts.
  • the measurement of the efficiency of the anti-convulsive actions of Ca salts has a certain significance in the choice of the Ca salts to be used in tetany treatment, whenever an emergency indicates a subcutaneous or intramuscular injection.
  • procaine bicarbonate is more efiective than its hydrochloride in respect to the incidence of convulsions and to the intensity and the duration of reaction.
  • Ca salts must be eliminated from clinical use in subcutaneous, intra-muscular and intra-spinal injections because of their locally irritating and necrotic reactions. Accordingly, the Ca halides arediscarded along with Ca gluconate which has only a slightly effective, anti-convulsive action.
  • those Ca salts that can be effectively used in clinical routine are the salicylate and the levulinate.
  • Ca levulinate is to be recommended. first because it is very soluble in water, is readily sterilized, and is non-toxic and non-irritating locally in therapeutic doses. Ca lactate is likewise effective, although it is less soluble and stable than the levulinate.
  • Convulsion index Ca salicylate 1 The quantity of Ca levulinate corresponding to 9 mg. Ca/kg. is 60 mg./kg. If the concentration is increased to mg./kg., then the 100 mg. of procaine/kg. are completely detoxified.
  • Butyn sulfate can likewis be studied. Selecting 25 mg. butyn/kg. with 18 mg. Ca/kg. and ac- .perimental disclosure is merely illustrative, "and cepting the average value of incidence with Ca levulinate as unity the following comparative table results: I
  • I I v 1.'A detoxified local anesthetic comprising a mixture containing a member selected from the group consisting of procaine and butyn and an organic calcium salt selected from the group consisting of levulinate, lactate and salicylate.
  • a method for detoxifying a member selected from the group consisting of procaine and butyn for use as a local anesthetic comprising the mixing of said member with an organic calcium salt selected from the group consisting of levulinate, lactate and salicylate prior to administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

Patented Jan." 6, 1942 UNITED STATES PIYATEN I T OFFICE METHOD AND MATERIAL FOR DETOXIFY- ING LOCAL ANESTHETICS Helene Wastl and Reinhard Beutner, Philadelphia, Pa., 'assignors to Hahnemann Research Foundation, Philadelphia, Pa., a corporation of Pennsylvania No Drawing. Application May 27, 1939, Serial No. 276,236
2 Claims.
Our invention refers generally to the detoxifia point of viewof holding the anesthetic 10- cally at the place of injectionhas a definitely practical significance; and for that reason adrenaline is usually added routinely to local anesthetics.
In many cases such a procedure is satisfactory. However, there are individuals in whom adrenaline induces inirnical effects, since adrenaline is a highlytoxic substance even in conjunction with a local anesthetic. Since it is diflicult to determine in advance the undue sensitivity of such individuals, it becomes eminently desirable to discover materials to be added to local anesthetics for the purpose of delaying their absorption, whether it be done by increasing the density of the membranes or by establishing local vasoconstruction. be harmless to the individual if they are to replace the adrenaline that accompanies the human use of local anesthetics.
Local anesthetics act on the central nervous system as a general poison when absorbed at a sufficiently rapid rate and with their elimination lagging behind at a certain rate. Convulsions and equilibrium disturbances are largely of a cortical origin. Therefore, one can determine, when studying the convulsions caused by toxic doses. of local anesthetics in animals, those substances, mostly Ca salts, which lead to a lesser incidence or to a complete disappearance of the aforesaid toxic effects. Although we have observed the effectiveness of our means for de- Such materials, obviously, must substances (dominant receptors) at the site of the action and also-with secondary receptors apart from the site of the action. The site of the action may be more or less irritable and the dominant receptors may be more or less accessible to the drug. However, there is little known about the factors that influence the rate of the chemical destruction of the drug in the animal body, those that change the action of the drug by influencing its milieu and those that modify the distribution of the drug between the dominant and the secondary receptors. But if two drugs have the same dominant receptors, it is likely that one drug will be more easily absorbed than the other, i. e., the recognized phenomenon of replacement becomes evident. Accordingly, detoxification of local anesthetics by the addition to them of other substances cannot be attributed solely to a single mechanism,, as, for
example, a knowledge of their local effects upon.
the site of injection. Combined local effects at the various sites of the action of a drug and a toxiiying local anesthetics in animal studies, yet
the same agencies in smaller dosage, are safely applicable, as attested, by clinical experience, to humans by replacing adrenaline with the Ca salts. Incidentally, the measurement of the efficiency of the anti-convulsive actions of Ca salts has a certain significance in the choice of the Ca salts to be used in tetany treatment, whenever an emergency indicates a subcutaneous or intramuscular injection.
Aside from the local effects of such additions to a local anesthetic, one must take into consideration whether or not the Ca salts act anticonvulsively on the central nervous system after having been absorbed. The real site of the action of a drug is unknown, but it is an accepted thesis that every drug must combine with unknown study of the detoxifying additions to itin variable and largely unknown interchanges and relations contribute toward the making of a more comprehensive and factual picture. In our research work, we first injected healthy guinea pigs intra-muscularly with a'number of local anesthetics like butyn sulfate, procaine HCl, procaine bicarbonate, and the like. The animals responded with uncoordinated movements, loss of equilibrium and a falling to their sides. convulsions then set in, alternately tonic and tetanic in type. Frequently, there was observed a marked opisthotonus and ultimately there developed a profound and persistent prostra-tion. However, recovery invariably followed,-
except in a few cases when the animals succumbed to respiratory failure when highly toxic doses had been administered.
The reaction of the drugs was observed as ended when the animals arose voluntarily, walked about or at least sat in their usual position. In border line case's, convulsions were provoked sooner by the attempts of the animals to move the fact that a seven day period usually elapsed (in some cases, a ten to twelve day period) between injections into an animal, yet not infrequently there were observed cumulative. effects in later injections, as evidenced by a higher nercentual incidence of convulsions.
Furthermore, we had to take in consideration, on the general principle of biological variation, the variations in sensitiveness or resistance of the numerous test animals. Because of such variability factors, pertinent results could be achieved only by studying for every combination of a drug with added substances a. large group of animals and by treating out data thus obtained in a statistical analysis of the number of times that a positive reaction occurred after injection, of the type and reaction, and of the percentual incidence in the different groups. In this way, average results and the range of variations were determined. Individual reactions were distributed over a fairly wide range, but as Treva has demonstrated, irregular results disappear when a sufficiently large number of animals are tested.
In our investigation, over 3500 experiments were performed in the following categories:
In groups 1 and 2, varying concentrations of procaine bicarbonate and butyn sulfate were administered alone into the guinea pigs. Our results indicate that butyn is far more toxic than procaine and a smaller dosage must be used. In the administration of butyn a dose of 50 mg. of butyn/kg. of body weight was found to be lethal and a dose of 25 mgJkg. was observed as sublethal.
the duration of the Furthermore, it was observed that procaine bicarbonate is more efiective than its hydrochloride in respect to the incidence of convulsions and to the intensity and the duration of reaction.
In groups 3 and 4, the aforesaid characteristics of procaine and butyn were confirmed by experiments testing the time for the reflexdisappearance in frogs and for the corneal reflex-disappearance in rabbits.
- In group 5, over a thousand experiments were performed in which various Ca salts were used in conjunction with procaine I-ICl in a dosage of 100 mg. procaine/1 kg. of weight. Among the Ca salts thus used were the salicylate, the chlor-acetate, the lactate, the iodide, the bromide, the chloride, the gluconate, the orthoiodoxy-benzoate and the levulinate. Our results disclose that the most efiective anti-convulsant in this group is Ca salicylate and the least effective, Ca ortho-iodoxy-benzoate. Ca gluconate has almost as little effect as Ca orthoiodoxy-benzoate.
In group 6, many experiments were performed with the Ca salts in conjunction with procaine H01 in a. dosage of 200 mgJkg. of weight. Our results indicate that the protective effect of the .Ca salts varies in the manner demonstrated Joy the experiments of group 5, in spite of the fact that the double dose of procaine is highly toxic and suhlethal.
In group 7, CaClz was added to butyn sulfate,
though in higher concentrations insoluble CaSO4 is precipitated. Our results show that CaClz exerts a definite protective action against convulsions. However, we obtained evidence to the efiect' that repeated injections lead to an increasingly higher incidence of convulsions.
In group 8, Ca gluconate and Ca lactate were studied in conjunction with butyn sulfate. As in the case of procaine HCl, the detoxifying effect of Ca gluconate on butyn is negligible; but the effect of Ca lactate is pronounced in even fairly low concentrations.
In group 9, the detoxifying effect of Ca levulinate on butyn sulfate was exhaustively studied with'definitely positive results.
In group 10, the effects ofother (than Ca) salts were studied alone and in conjunction with the Ca salts from the view point of their influence on the detoxification of procaine HCl. KCl alone with procaine decreases somewhat the incidence of convulsions. When KCl was combined with Ca salts, the anti-convulsant eflect became greaterbut not so striking as was anticipated; MgCh in conjunction with CaCl: is far less eflective than 08.012 alone in decreasi the incidence of convulsions induced by procaine. In group 11, we undertook experiments with adrenaline additions to procaine HCl and the results demonstrated combinations very effective in decreasing the incidence of convulsions .and the duration of the positive reaction.
In group 12, we studied the effects of addition of luminal and nernbutal to procaine HQ with comparatively negative results. In the case of nembutal, the procaine convulsions occur and disappear before the depressing effect of nembutal on the central nervous system is asserted.
In the aforesaid groups of experiments extensive material has been obtained for the purpose of presenting a comparative study of the Ca salts in so far as their efliciency in detoxifying local anesthetics is of moment in clinical application. Various theories attempt to explain the effect of CaClz on the toxicity of cocaine and procaine. It has been suggested that the antagonism of cocaine and CaCl: depends on a change in the state of the lipoids, particularly lecithin which has an aflinity for cocaine and CaClz. Also, the conjecture has been offered that substances having opposite effects on permeability can antagonize each other as do the alkaloids and salts. Furthermore, Ca has the effect of increasing colloid density and should induce, therefore, a decreased rate of absorption.
But irrespective of the explanations for the mechanism of the changes produced in the effects of procaine and butyn, by the Ca salts, a number of the Ca salts must be eliminated from clinical use in subcutaneous, intra-muscular and intra-spinal injections because of their locally irritating and necrotic reactions. Accordingly, the Ca halides arediscarded along with Ca gluconate which has only a slightly effective, anti-convulsive action. Among those Ca salts that can be effectively used in clinical routine are the salicylate and the levulinate. Of these, Ca levulinate is to be recommended. first because it is very soluble in water, is readily sterilized, and is non-toxic and non-irritating locally in therapeutic doses. Ca lactate is likewise effective, although it is less soluble and stable than the levulinate.
The following tabl is signficant. We have selected procaine HCl mgJkg.) with the addition of Ca salts of 9 mg. of the Ca to 1 kg. and have regarded the average percentage of convolutions occurring with Ca salicylate as unity.
. Convulsion index Ca salicylate 1 The quantity of Ca levulinate corresponding to 9 mg. Ca/kg. is 60 mg./kg. If the concentration is increased to mg./kg., then the 100 mg. of procaine/kg. are completely detoxified.
Butyn sulfate can likewis be studied. Selecting 25 mg. butyn/kg. with 18 mg. Ca/kg. and ac- .perimental disclosure is merely illustrative, "and cepting the average value of incidence with Ca levulinate as unity the following comparative table results: I
Ca levulinate 1 Ca lactate 4.88 CaClz 11.24 Ca gluconate 18.14
Throughout our many experiments involving the conjunction of Ca salts with local anesthetics as applicable to the incidence of convulsions in animals, we have come to these definite generalizations:
It is to be understood that the aforesaid exis not to be construed as restrictive of the scope nor of the spirit of our invention, which has been further defined by the following annexed claims.
We claim: I I v 1.'A detoxified local anesthetic comprising a mixture containing a member selected from the group consisting of procaine and butyn and an organic calcium salt selected from the group consisting of levulinate, lactate and salicylate.
2. A method for detoxifying a member selected from the group consisting of procaine and butyn for use as a local anesthetic, comprising the mixing of said member with an organic calcium salt selected from the group consisting of levulinate, lactate and salicylate prior to administration.
HELENE WASTL. REINHARD BEUI'NER.
US276236A 1939-05-27 1939-05-27 Method and material for detoxifying local anesthetics Expired - Lifetime US2268915A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US276236A US2268915A (en) 1939-05-27 1939-05-27 Method and material for detoxifying local anesthetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US276236A US2268915A (en) 1939-05-27 1939-05-27 Method and material for detoxifying local anesthetics

Publications (1)

Publication Number Publication Date
US2268915A true US2268915A (en) 1942-01-06

Family

ID=23055782

Family Applications (1)

Application Number Title Priority Date Filing Date
US276236A Expired - Lifetime US2268915A (en) 1939-05-27 1939-05-27 Method and material for detoxifying local anesthetics

Country Status (1)

Country Link
US (1) US2268915A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2518525A (en) * 1946-08-12 1950-08-15 Curtis David Levulinic acid salts of amino benzoates
US3118890A (en) * 1961-07-24 1964-01-21 William L Gould Procaine orotate
US3347746A (en) * 1963-10-23 1967-10-17 Nyegaard & Co As Injectable solution of an amine salt of a radiopaque iodinated organic acid containing calcium ions
US4963345A (en) * 1988-07-18 1990-10-16 Forrest Kim K Injectable local anesthetic antidote

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2518525A (en) * 1946-08-12 1950-08-15 Curtis David Levulinic acid salts of amino benzoates
US3118890A (en) * 1961-07-24 1964-01-21 William L Gould Procaine orotate
US3347746A (en) * 1963-10-23 1967-10-17 Nyegaard & Co As Injectable solution of an amine salt of a radiopaque iodinated organic acid containing calcium ions
US4963345A (en) * 1988-07-18 1990-10-16 Forrest Kim K Injectable local anesthetic antidote

Similar Documents

Publication Publication Date Title
Gunderson et al. Nerve agents: a review
Rhoads Nitrogen mustards in the treatment of neoplastic disease: Official statement
Calvert et al. Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II
Tilson et al. Conditioned drug effects and absence of tolerance to d-amphetamine induced motor activity
Jaffe et al. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: A pilot study
Feller et al. Baseline results of therapy for burned patients
Nomoto et al. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset
Petty Organic phosphate insecticide poisoning: residual effects in two cases
US2268915A (en) Method and material for detoxifying local anesthetics
Woolley Production of abnormal (psychotic?) behavior in mice with lysergic acid diethylamide, and its partial prevention with cholinergic drugs and serotonin
Doshay et al. Treatment of paralysis agitans with orphenadrine (Disipal) hydrochloride: results in one hundred seventy-six cases
Awadzi et al. The chemotherapy of onchocerciasis III: A comparative study of diethylcarbamazine (DEC) and metrifonate
Rodgers et al. Shock‐induced aggression and pain sensitivity in the rat: Catecholamine involvement in the corticomedial amygdala
Hirshaut et al. The use of long-term human leukocyte cell cultures as models for the study of antileukemic agents
Tompsett XIV Relation of Dosage to Streptomycin Toxicity
Steiner et al. Central cholinolytic action of chlorpromazine
Orme et al. Metoclopramide and tardive dyskinesia in the elderly.
Gillessen et al. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
Gamba et al. Synoviorthesis versus synovectomy in the treatment of recurrent haemophilic haemarthrosis: long-term evaluation
Dubois et al. Prevention and treatment of the gastric symptoms of radiation sickness
Hamburger et al. The problem of the dangerous carrier of hemolytic streptococci: III. The chemotherapeutic control of nasal carriers
Taylor et al. Comparison of 5-Azacytidine (NSC-102816) With CCNU (NSC-79037) in the Treatment of Patients With Breast Cancer and Evaluation of the Subsequent Use of Cyclophosphamide (NSC-26271)" 4
Kaelber et al. Drug (Tremorine)-Induced Tremor in the Cat: Abolition by Differential Transections of the Neuraxis
Sterling Anaphylactic shock following penicillin therapy in bronchial asthma
GOKHALE et al. Participation of an unusual ganglionic pathway in the mediation of the pressor effect of physostigmine in the rat